Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronidazole for Fusobacterium Nucleatum Eradication in Postoperative Colorectal Cancer
NCT04264676Phase 2Unknown
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Mar 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) comparing Metronidazole with Placebo (2 arms). Primary endpoint: Disease Free Survival at 5 years. Status: unknown.
02
Drugs
metronidazole
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04264676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264676.